Uae Pharmaceutical Cdmo Market Size & Outlook, 2025-2033
Global Market
Related Markets
UAE pharmaceutical cdmo market highlights
- The UAE pharmaceutical cdmo market generated a revenue of USD 826.9 million in 2024 and is expected to reach USD 1,330.2 million by 2033.
- The UAE market is expected to grow at a CAGR of 5.4% from 2025 to 2033.
- In terms of segment, api was the largest revenue generating product in 2024.
- API is the most lucrative product segment registering the fastest growth during the forecast period.
Pharmaceutical cdmo market data book summary
| Market revenue in 2024 | USD 826.9 million |
| Market revenue in 2033 | USD 1,330.2 million |
| Growth rate | 5.4% (CAGR from 2025 to 2033) |
| Largest segment | Api |
| Fastest growing segment | API |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | API, Drug Product |
| Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
Other key industry trends
- In terms of revenue, UAE accounted for 0.5% of the global pharmaceutical cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, South Africa pharmaceutical cdmo market is projected to lead the regional market in terms of revenue in 2033.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 3,592.9 million by 2033.
The pharmaceutical CDMO market is continuously growing in the UAE due to factors such as a rising prevalence of several chronic diseases, growing investments in complex biologic molecules development, a supportive regulatory environment.
Entry of new market players, and growing year-onyear investments of foreign pharmaceutical companies & CDMOs. Moreover, the market is fueled by domestic players who expand their pharmaceutical production capacities & geographical presence through various strategies.
Such factors support the production of pharmaceutical products in the country. The number of CDMOs in the UAE has been increasing since 2000. The country offers favorable incentive policies that have attracted leading pharmaceutical companies, such as Pfizer, AstraZeneca, and Amgen.
No credit card required*
Publish Date: Sep 15, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Pharmaceutical CDMO Market Scope
Pharmaceutical CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
UAE Pharmaceutical CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmaceutical CDMO Market Outlook will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 81.52% in 2024.
Horizon Databook has segmented the Uae pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2021 to 2033.
The pharmaceutical CDMO market is continuously growing in the UAE due to factors such as a rising prevalence of several chronic diseases, growing investments in complex biologic molecules development, a supportive regulatory environment.
Entry of new market players, and growing year-onyear investments of foreign pharmaceutical companies & CDMOs. Moreover, the market is fueled by domestic players who expand their pharmaceutical production capacities & geographical presence through various strategies.
Such factors support the production of pharmaceutical products in the country. The number of CDMOs in the UAE has been increasing since 2000. The country offers favorable incentive policies that have attracted leading pharmaceutical companies, such as Pfizer, AstraZeneca, and Amgen.
- Uae Pharmaceutical Cdmo Market Product Outlook (Revenue, USD Million , 2021-2033)
- API
- Drug Product
- Uae Pharmaceutical Cdmo Market Work Flow Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- Uae Pharmaceutical Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Hormonal Disorders
- Hematological Disorders
- Others
- Uae Pharmaceutical Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
- Contract Development
- Contract Manufacturing
- Packaging
- Quality Control and Assurance
- Others
- Uae Pharmaceutical Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Reasons to subscribe to Pharmaceutical CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmaceutical CDMO Market Outlook databook
- Our clientele includes a mix of Pharmaceutical CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE Pharmaceutical CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into UAE Pharmaceutical CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Uae Pharmaceutical Cdmo Market, 2021-2033 (US$M)
UAE Product - Pharmaceutical Cdmo Market Statistics, 2024 - 2033 (US$M)
